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# Variable / Field Name Field Label
Field Note
Field Attributes (Field Type, Validation, Choices,
Calculations, etc.)
Instrument: Physician Survey (physician_survey)  Enabled as survey
1 record_id Record ID text
University of Kentucky
Center for Clinical and Translational Research
Methodological Advances in Evaluating Abuse-deterrent Opioid Analgesics -
Prescriber Survey
 Codebook 
2 opening You are invited to participate in a survey collecting information
and opinions related to the prescribing and dispensing of
abuse-deterrent formulation opioid analgesics. This study is
being conducted on behalf of the U.S. Food and Drug
Administration by researchers at the University of Kentucky
Colleges of Pharmacy and Public Health.
You have been asked to participate in this survey because you
are a licensed physician with the ability to prescribe controlled
substances in the state of Kentucky. If you voluntarily complete
the survey, you will be one of approximately 1,500 physicians
to do so. The survey will take approximately 10 minutes to
complete. 
The survey asks about your prescribing of abuse-deterrent
formulation opioid analgesics. The information generated from
this research will assist in our understanding of how these
medications are being utilized in practice. 
Your response to the survey is anonymous. Neither the
researchers nor the licensure board will know who did, or did
not, respond to the survey. The research team will not attempt
to trace responses back to individuals. There are no known
risks associated with disclosure of your opinions about the
prescribing and dispensing of abuse-deterrent formulations of
opioid analgesics. Your information will be kept secure to the
extent provided by law.
You may receive two additional email invitations to participate
in this survey over the next two weeks. If you have already
responded, or elect not to respond to the survey, please ignore
these additional emails. 
Taking part in this research is completely voluntary. If you
choose not to participate, there will be no penalty to you. You
are free to skip any question that you do not want to answer,
and you can discontinue the survey at any time. Although you
will not personally benefit by completing the survey, the
information that you provide may help us understand how
abuse-deterrent formulations might be used more effectively. 
This study has been reviewed by the University of Kentucky
Medical Institutional Review Board. If you have questions about
this study, you may call Patricia Freeman at 859-323-1381 or
Svetla Slavova at 859-323-7873. If you have any questions
about your rights as a volunteer in this research, you may
contact the staff in the Office of Research Integrity at the
University of Kentucky at 859-257-9428 or toll free at 1-866-
400-9428. 
Thank you for your time and we appreciate your consideration
in completing this survey.
Patricia Freeman, PhD
Associate Professor
University of Kentucky College of Pharmacy
Svetla Slavova, PhD
Associate Professor
University of Kentucky College of Public Health
descriptive
3 contr_sub Section Header: OMB Control No.: 0910-0847 Expiration Date: 11/30/2020
Paperwork Reduction Act Statement: According to the Paperwork Reduction Act
of 1995, an agency may not conduct or sponsor and a person is not required to
respond to a collection of information unless it displays a valid OMB control
number. The valid OMB control number for this information collection is 0910-
0847, and the expiration date is 11/30/2020. The time required to complete
this information collection is estimated to average 10 minutes per response,
including the time for reviewing instructions, searching existing data sources,
gathering and maintaining the data needed, and completing and reviewing the
collection of information. Send comments regarding this burden estimate or
any other aspects of this collection of information, including suggestions for
reducing burden, to PRAStaff@fda.hhs.gov. This study is being conducted on
behalf of the U.S. Food and Drug Administration by researchers at the
University of Kentucky Colleges of Pharmacy and Public Health.





Stop actions on 0
4 no_cs
Show the field ONLY if:
[contr_sub] = '0'
Thank you for your willingness to participate. This survey
focuses on the prescribing of opioid analgesics. We look
forward to your participation in future surveys.
descriptive
5 section2_preamb Section Header: Section I. Questions about your perception of abuse-deterrent
formulation opioids.
One of the ways that the U.S. Food and Drug Administration
(FDA) has tried to address the opioid epidemic is by approving
opioid analgesic products that are designed to be harder to
manipulate and abuse. These so-called 'abuse-deterrent
formulations' (e.g. OxyContin®, Embeda®, etc.) are intended to
make certain types of abuse, such as crushing a tablet to snort
or dissolving a capsule to inject, more difficult or less
rewarding.
descriptive
6 adf_familiar Considering your experience prescribing opioid analgesics,
how would you rate your familiarity with abuse-deterrent
formulation opioids?
radio






7 smok Section Header: Individuals who misuse/abuse prescription opioids do so
using varied routes of administration. In your professional opinion, how
effective are abuse-deterrent formulation opioids in mitigating abuse/misuse
by each of these specific routes?
Smoking
radio (Matrix)





8 snort Snorting radio (Matrix)





9 chew Chewing or dissolving before swallowing radio (Matrix)





10 intact Swallowing intact radio (Matrix)





11 injec Injection (intravenous, intramuscular, or subcutaneous) radio (Matrix)





12 labeling_opinion Please indicate the extent to which you agree or disagree with
the following statement: 
In my professional opinion, to gain and maintain FDA-approval,










Show the field ONLY if:
[labeling_opinion] = '4'
If you selected "Strongly agree," please elaborate. text
Custom alignment: RH
14 label_strongdis
Show the field ONLY if:
[labeling_opinion] = '1'
If you selected "Strongly disagree," please elaborate. text
Custom alignment: RH
15 early_adopt Section Header: Section II. Questions about your experience prescribing
medications newly-approved by the FDA and abuse-deterrent formulation
opioid analgesics.
Which of these describes you well when it comes to prescribing
medications newly approved by the FDA? (select all that apply)
checkbox
1 early_adopt___1 Usually prescribe new
medications before others do
2 early_adopt___2 Prefer medications which
have worked well for patients
in the past
3 early_adopt___3 Like being able to share with
colleagues about new
medications I've prescribed
4 early_adopt___4 Like the variety of prescribing
new medications
5 early_adopt___5 Feel more comfortable using
familiar medications







Show the field ONLY if:
[early_adopt(7)] = '1'
If you selected 'Other,' please describe. text
Custom alignment: RH
17 cons_adf_yn When making prescribing decisions regarding which opioid
analgesic to prescribe, do you consider whether or not the






Show the field ONLY if:
[cons_adf_yn] = '1'
Section Header: To what extent do each of the following patient-specific
factors influence your decision to prescribe an abuse-deterrent formulation
opioid over a non-abuse-deterrent opioid analgesic?







Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'








Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[risk_strat] = '3' or [risk_strat]
= '4'
Which of the following risk-stratification tools do you most
commonly utilize?
radio
1 Opioid risk tool
2 Screener and Opioid Assessment for Patients
with Pain - Version 1 (SOAPP-1)
3 Screener and Opioid Assessment for Patients
with Pain - Revised (SOAPP-R)




Show the field ONLY if:
[riskstrat] = '5'
If you selected 'Other,' please provide the name of the risk-




Show the field ONLY if:
[cons_adf_yn] = '1'
Section Header: To what extent do each of the following non-patient-specific
factors influence your decision to prescribe an abuse-deterrent formulation
opioid over a non-abuse deterrent opioid analgesic?







Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'






Show the field ONLY if:
[cons_adf_yn] = '1'







38 embeda Section Header: For each of the following abuse-deterrent formulation
opioids, please indicate the frequency with which you have prescribed them in
your practice.




2 Rarely (i.e. a few times a year)
3 Occasionally (i.e. monthly)
4 Frequently (i.e. weekly)
5 Very frequently (i.e. daily)
39 hysinglaer Hysingla® ER (hydrocodone bitartrate extended-release) radio (Matrix)
1 Never
2 Rarely (i.e. a few times a year)
3 Occasionally (i.e. monthly)
4 Frequently (i.e. weekly)
5 Very frequently (i.e. daily)
40 morphabonder MorphaBond® ER (morphine sulfate extended-release) radio (Matrix)
1 Never
2 Rarely (i.e. a few times a year)
3 Occasionally (i.e. monthly)
4 Frequently (i.e. weekly)
5 Very frequently (i.e. daily)
41 xtampzaer Xtampza® ER (oxycodone extended-release) radio (Matrix)
1 Never
2 Rarely (i.e. a few times a year)
3 Occasionally (i.e. monthly)
4 Frequently (i.e. weekly)
5 Very frequently (i.e. daily)
42 oxycontin OxyContin® (oxycodone hydrochloride extended-release) radio (Matrix)
1 Never
2 Rarely (i.e. a few times a year)
3 Occasionally (i.e. monthly)
4 Frequently (i.e. weekly)
5 Very frequently (i.e. daily)
43 oxyrsns
Show the field ONLY if:
[oxycontin] = '2' or [oxyconti
n] = '3' or [oxycontin] = '4' or
[oxycontin] = '5'
In general, please indicate the primary reason you have
prescribed OxyContin®.
radio
1 It is an extended-release opioid product covered
by most third-party payers
2 It is an abuse-deterrent formulation
3 It is an appropriate extended release regimen
for patients who have been on oxycodone
immediate-release
4 It has been an effective treatment for previous
patients
5 Patient was started on OxyContin by another
provider and appears to benefitting from it
Custom alignment: LV
44 generic
Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'
Section Header: For the abuse-deterrent formulations that you have NEVER
prescribed, please indicate to what extent the following factors generally
influenced your decision NOT to prescribe these agents?








Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'






Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'






Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'
Lack of third-party coverage or high copays makes them







Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'








Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'








Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'








Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'








Show the field ONLY if:
[embeda] = '1' or [hysinglaer]
= '1' or [morphabonder] = '1'
or [xtampzaer] = '1' or [oxyco
ntin] = '1'
Evidence-based guidelines do not list abuse-deterrent







53 pt_prefer Section Header: Section III. Communication with patients and pharmacists
regarding abuse deterrent formulation opioids.
To your recollection, have any of your patients ever specifically
requested to receive an abuse-deterrent opioid formulation






Show the field ONLY if:
[pt_prefer] = '1'
What circumstances best describe the reason(s) a patient
specifically requested an abuse-deterrent formulation opioid
instead of a non-abuse-deterrent opioid? (select all that apply)
checkbox
1 runs_pt_request___1 Past medical history




3 runs_pt_request___3 Belief that abuse-
deterrent formulations




Show the field ONLY if:
[runs_pt_request(4)] = '1'
If you selected 'Other,' please describe. text
Custom alignment: LV
56 pt_req_noadf
Show the field ONLY if:
[embeda] = '2' or [embeda] =
'3' or [embeda] = '4' or [embe
da] = '5' or [hysinglaer] = '2' o
r [hysinglaer] = '3' or [hysingla
er] = '4' or [hysinglaer] = '5' or
[morphabonder] = '2' or [mor
phabonder] = '3' or [morphab
onder] = '4' or [morphabonde
r] = '5' or [xtampzaer] = '2' or
[xtampzaer] = '3' or [xtampza
er] = '4' or [xtampzaer] = '5' o
r [oxycontin] = '2' or [oxyconti
n] = '3' or [oxycontin] = '4' or
[oxycontin] = '5'
To your recollection, has a patient to whom you prescribed an
abuse-deterrent formulation opioid ever specifically requested






Show the field ONLY if:
[pt_req_noadf] = '1'
Please describe the reason(s) the patient requested to switch
to a non-abuse-deterrent formulation opioid.
text
Custom alignment: RH
58 rph_contact To your recollection, have you ever been contacted by a
pharmacist who recommended an abuse-deterrent






59 rphnonadf To your recollection, have you ever been contacted by a
pharmacist to request substitution of a non-abuse-deterrent
formulation opioid for an abuse-deterrent formulation opioid?






Show the field ONLY if:
[rphnonadf] = '1'
What circumstance(s) best describe(s) the reason(s) a
pharmacist contacted you to request substitution of a non-
abuse-deterrent formulation opioid for an abuse-deterrent
formulation opioid? (select all that apply)
checkbox
1 subrsns___1 Abuse-deterrent formulation was
out of stock
2 subrsns___2 Cost to patient was lower for non-
abuse-deterrent formulation
3 subrsns___3 Patient preferred / requested a
non-abuse-deterrent formulation






Show the field ONLY if:
[subrsns(5)] = '1'
If you selected 'Other,' please describe. text
Custom alignment: RH
62 mddecis
Show the field ONLY if:
[rphnonadf] = '1'







Show the field ONLY if:
[embeda] = '2' or [embeda] =
'3' or [embeda] = '4' or [embe
da] = '5'
Section Header: Section IV. Questions about third party payer requirements
for abuse deterrent formulation opioids. For each of the following abuse-
deterrent formulation opioids that you HAVE prescribed, please indicate how
often prescriptions are subject to additional requirements from third-party
payers (e.g. prior authorization).






4 I am unsure how often prescriptions are subject
to additional requirements.
64 algnisyh
Show the field ONLY if:
[hysinglaer] = '2' or [hysinglae
r] = '3' or [hysinglaer] = '4' or
[hysinglaer] = '5'




4 I am unsure how often prescriptions are subject
to additional requirements.
65 dnobahprom
Show the field ONLY if:
[morphabonder] = '2' or [mor
phabonder] = '3' or [morphab
onder] = '4' or [morphabonde
r] = '5'




4 I am unsure how often prescriptions are subject
to additional requirements.
66 nitnocyxo
Show the field ONLY if:
[oxycontin] = '2' or [oxyconti
n] = '3' or [oxycontin] = '4' or
[oxycontin] = '5'




4 I am unsure how often prescriptions are subject
to additional requirements.
67 azpmatx
Show the field ONLY if:
[xtampzaer] = '2' or [xtampza
er] = '3' or [xtampzaer] = '4' o
r [xtampzaer] = '5'




4 I am unsure how often prescriptions are subject
to additional requirements.
68 state_legis At this time, would you support state legislation mandating







Show the field ONLY if:
[state_legis] = '1'
Please elaborate as to why you would support this legislation. text
70 leg_no_support_elab
Show the field ONLY if:
[state_legis] = '0'
Please elaborate as to why you would not support this
legislation.
text
71 comm Section Header: Section V. Questions about your perception of opioid
misuse/abuse. Please indicate to what extent you agree or disagree with the
following statements.








72 pract The misuse/abuse of prescription opioids is a problem among















74 abuse_roa In your professional opinion, which of the following routes of





3 Chewing or dissolving before swallowing
4 Swallowing intact




75 kasper Section Header: In your professional opinion, how effective are the following
strategies in mitigating the misuse/abuse of prescription opioids?
Checking the prescription drug monitoring program (KASPER)
radio (Matrix)





76 rphcounts Pharmacist-driven pill counts radio (Matrix)





77 adfopioids Abuse-deterrent formulation opioids radio (Matrix)





78 urineds Urine drug screening radio (Matrix)





79 prescrpillcounts Prescriber-driven pill counts radio (Matrix)





80 lockinprogram Payer restriction programs to a single pharmacy and/or single
prescriber (e.g. lock-in program)
radio (Matrix)





81 dslimits Prescribing (days' supply) limits radio (Matrix)





82 gender Section Header: Section VI. Questions about you and your practice.




3 Prefer not to answer
4 Prefer to self-describe
Custom alignment: LV
83 gend_othr
Show the field ONLY if:
[gender] = '4'
If you selected 'Prefer to self-describe,' you may do so here. text
Custom alignment: RH
84 years_prac Please indicate your total number of years in practice following
completion of residency training.
radio
1 Currently in residency training
2 < 5
3 5 -15
4 16 - 25
5 26 - 35
6 > 35
Custom alignment: LV









9 Hematology & Oncology
10 Internal medicine
11 Neurology or Neurological surgery





17 Pediatrics or Neonatal-Perinatal medicine
18 Plastic surgery
19 Psychiatry





Show the field ONLY if:
[specialty_type] = '22'
If you selected 'Other,' please describe. text
Custom alignment: RH
87 county_prac In which county is your primary practice site located (i.e. the































































































































2 Small private group practice (5 or less
practitioners)






8 Managed care organization





Show the field ONLY if:
[prac_type] = '10'
If you selected 'Other,' please describe. text
Custom alignment: RH
90 no_patients On average, across all practice sites (primary practice and other







91 ce_yn To your recollection, have you ever completed continuing
education that discussed the use of abuse-deterrent





92 finalthoughts Section Header: Section VII. Opportunity to provide additional thoughts on
survey topics.
Please share any additional thoughts you have about abuse-
deterrent formulation opioids and opioid misuse/abuse.
notes
93 physician_survey_complete Section Header: Form Status
Complete?
dropdown
0 Incomplete
1 Unverified
2 Complete
